Adagio Medical (NASDAQ:ADGM) announced the first patient treated in a clinical study evaluating its next-generation vCLAS Ultra Ultra-Low Temperature Ablation system for sustained monomorphic ventricular tachycardia.
Adagio Medical Holdings (NASDAQ:ADGM), a specialist in catheter ablation technologies for cardiac arrhythmias, reported a substantial narrowing of its net loss for the fiscal year ended Dec. 31, 2025, as the company realized the benefits of an aggressive cost-reduction strategy and a streamlined corporate profile.
Adagio Medical Holdings (NASDAQ:ADGM) unveiled positive six-month results from its FULCRUM-VT clinical trial on Monday, providing the foundational data required for its forthcoming Food and Drug Administration (FDA) Premarket Approval application.
Adagio Medical Holdings (NASDAQ:ADGM) announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT clinical trial.
